The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.
The US approval sparks a $125m payment to Daiichi Sankyo from AZ – the first milestone payment in the alliance. ... Sales of Enhertu in the US will be booked by Daiichi Sankyo with AZ claiming a share of gross profits.
Among the rivals is Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan (DS-8201), another ADC currently under regulatory review for patients with advanced HER2-positive breast cancer that have failed Kadcyla
Will rival Roche's HER2 franchise if approved. AstraZeneca’s big bet on a Daiichi Sankyo-developed HER2-targeting antibody-drug conjugate looks like its about to pay off, after delivering ... AZ and Daiichi Sankyo are looking at a possible approval for
US-based biotech is arguing the legal action is improper. Seattle Genetics has asked a court to dismiss a lawsuit brought a few weeks ago by Japan’s Daiichi Sankyo centring ... The two companies previously collaborated on ADC drug development between
Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”. ... The original agreement between the companies cover ADCs
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...